©The Author(s) 2026.
World J Hepatol. Feb 27, 2026; 18(2): 114481
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114481
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114481
Table 5 Adjusted Cox regression for associations between immunosuppression type and all-cause mortality amongst autoimmune hepatitis patients with coronavirus disease 2019: Sensitivity analysis for sub-population with full model for end stage liver disease 3.0 score
| Immunosuppressant | Hazard ratio | P value | 95%CI |
| Prednisone | 0.25 | 0.11 | 0.05-1.35 |
| Azathioprine | 0.06 | 0.25 | 0.00-7.24 |
| Budesonide | 12.2 | 0.30 | 0.11-1321.74 |
| Tacrolimus | 1.51 | 0.74 | 0.14-16.50 |
| Mycophenolate mofetil | NA | NA | NA, NA |
| Cyclosporine | 1.75e-09 | 1.00 | 0.00 to infinity |
- Citation: Rai K, Lindquist KJ, Kornak J, Ge J. Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis. World J Hepatol 2026; 18(2): 114481
- URL: https://www.wjgnet.com/1948-5182/full/v18/i2/114481.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i2.114481